Long-term protective effect of atorvastatin in permanent focal cerebral ischemia

Research output: Contribution to journalArticle

Standard

Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. / Yrjanheikki, J; Koistinaho, J; Kettunen, N; Kauppinen, Risto; Appel, K; Hull, M; Fiebich, BL.

In: Brain Research, Vol. 1052, 09.08.2005, p. 174-179.

Research output: Contribution to journalArticle

Harvard

Yrjanheikki, J, Koistinaho, J, Kettunen, N, Kauppinen, R, Appel, K, Hull, M & Fiebich, BL 2005, 'Long-term protective effect of atorvastatin in permanent focal cerebral ischemia', Brain Research, vol. 1052, pp. 174-179. https://doi.org/10.1016/j.brainres.2005.06.004

APA

Yrjanheikki, J., Koistinaho, J., Kettunen, N., Kauppinen, R., Appel, K., Hull, M., & Fiebich, BL. (2005). Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Research, 1052, 174-179. https://doi.org/10.1016/j.brainres.2005.06.004

Vancouver

Author

Yrjanheikki, J ; Koistinaho, J ; Kettunen, N ; Kauppinen, Risto ; Appel, K ; Hull, M ; Fiebich, BL. / Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. In: Brain Research. 2005 ; Vol. 1052. pp. 174-179.

Bibtex

@article{e67a5120ca614b13a614f0deace53287,
title = "Long-term protective effect of atorvastatin in permanent focal cerebral ischemia",
abstract = "Statins exert beneficial effects in brain diseases including stroke. Here, we investigated whether oral prophylactic atorvastatin provides long-term neuroprotection and functional recovery in permanent middle cerebral artery occlusion (pMCAO), and whether cerebral hemodynamics are affected. Male Long-Evans rats were treated with 10 mg/kg oral atorvastatin for 14 days and subjected to pMCAO. Cerebral hemodynamics were measured by bolus tracking MRI and laser Doppler flowmetry (LDF). Infarct volume was quantified at 1 week by T2-MRI and at 3 weeks by histology. Rats were also subjected to neuroscoring and cylinder test. The number of animals per group was 10. The infarct volumes were 100.8 +/- 8.2 and 47.3 +/- 5.5 mm(3) in vehicle, and 68.7 +/- 11.0 and 28.6 +/- 3.82 mm(3) in atorvastatin group at 7 and 21 days post-ischemia, respectively (mean +/- SEM). Atorvastatin significantly reduced infarct volume both at 7 and 21 days (P = 0.04 and 0.03, respectively, 1-way ANOVA). Interestingly, no improvement in cerebral hemodynamic parameters was observed in atorvastatin treated animals. The vehicle group recovered normal neuroscore at day 13, whereas atorvastatin group recovered already at day 10 after pMCAO. All treatment groups preferred to use the unaffected forelimb for rearing in Cylinder test, whereas the defected forelimb use was minimal in all groups. These results suggest that oral atorvastatin protects cerebral tissue against the subsequent pMCAO without influencing cerebral hemodynamic parameters, and it may well be that persons with ongoing atorvastatin treatment benefit in the incidence of stroke.",
author = "J Yrjanheikki and J Koistinaho and N Kettunen and Risto Kauppinen and K Appel and M Hull and BL Fiebich",
year = "2005",
month = aug,
day = "9",
doi = "10.1016/j.brainres.2005.06.004",
language = "English",
volume = "1052",
pages = "174--179",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Long-term protective effect of atorvastatin in permanent focal cerebral ischemia

AU - Yrjanheikki, J

AU - Koistinaho, J

AU - Kettunen, N

AU - Kauppinen, Risto

AU - Appel, K

AU - Hull, M

AU - Fiebich, BL

PY - 2005/8/9

Y1 - 2005/8/9

N2 - Statins exert beneficial effects in brain diseases including stroke. Here, we investigated whether oral prophylactic atorvastatin provides long-term neuroprotection and functional recovery in permanent middle cerebral artery occlusion (pMCAO), and whether cerebral hemodynamics are affected. Male Long-Evans rats were treated with 10 mg/kg oral atorvastatin for 14 days and subjected to pMCAO. Cerebral hemodynamics were measured by bolus tracking MRI and laser Doppler flowmetry (LDF). Infarct volume was quantified at 1 week by T2-MRI and at 3 weeks by histology. Rats were also subjected to neuroscoring and cylinder test. The number of animals per group was 10. The infarct volumes were 100.8 +/- 8.2 and 47.3 +/- 5.5 mm(3) in vehicle, and 68.7 +/- 11.0 and 28.6 +/- 3.82 mm(3) in atorvastatin group at 7 and 21 days post-ischemia, respectively (mean +/- SEM). Atorvastatin significantly reduced infarct volume both at 7 and 21 days (P = 0.04 and 0.03, respectively, 1-way ANOVA). Interestingly, no improvement in cerebral hemodynamic parameters was observed in atorvastatin treated animals. The vehicle group recovered normal neuroscore at day 13, whereas atorvastatin group recovered already at day 10 after pMCAO. All treatment groups preferred to use the unaffected forelimb for rearing in Cylinder test, whereas the defected forelimb use was minimal in all groups. These results suggest that oral atorvastatin protects cerebral tissue against the subsequent pMCAO without influencing cerebral hemodynamic parameters, and it may well be that persons with ongoing atorvastatin treatment benefit in the incidence of stroke.

AB - Statins exert beneficial effects in brain diseases including stroke. Here, we investigated whether oral prophylactic atorvastatin provides long-term neuroprotection and functional recovery in permanent middle cerebral artery occlusion (pMCAO), and whether cerebral hemodynamics are affected. Male Long-Evans rats were treated with 10 mg/kg oral atorvastatin for 14 days and subjected to pMCAO. Cerebral hemodynamics were measured by bolus tracking MRI and laser Doppler flowmetry (LDF). Infarct volume was quantified at 1 week by T2-MRI and at 3 weeks by histology. Rats were also subjected to neuroscoring and cylinder test. The number of animals per group was 10. The infarct volumes were 100.8 +/- 8.2 and 47.3 +/- 5.5 mm(3) in vehicle, and 68.7 +/- 11.0 and 28.6 +/- 3.82 mm(3) in atorvastatin group at 7 and 21 days post-ischemia, respectively (mean +/- SEM). Atorvastatin significantly reduced infarct volume both at 7 and 21 days (P = 0.04 and 0.03, respectively, 1-way ANOVA). Interestingly, no improvement in cerebral hemodynamic parameters was observed in atorvastatin treated animals. The vehicle group recovered normal neuroscore at day 13, whereas atorvastatin group recovered already at day 10 after pMCAO. All treatment groups preferred to use the unaffected forelimb for rearing in Cylinder test, whereas the defected forelimb use was minimal in all groups. These results suggest that oral atorvastatin protects cerebral tissue against the subsequent pMCAO without influencing cerebral hemodynamic parameters, and it may well be that persons with ongoing atorvastatin treatment benefit in the incidence of stroke.

UR - http://www.scopus.com/inward/record.url?scp=23644456682&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2005.06.004

DO - 10.1016/j.brainres.2005.06.004

M3 - Article

C2 - 16023089

VL - 1052

SP - 174

EP - 179

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -